NCT01122979 - Evaluation of the Safety and Efficacy of Insulin Glargine + Glulisine or Insulin Regular + NPH Insulin (Isophane Insulin) Use in Type 2 Diabetes Mellitus Patients With Moderate Renal Failure. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2013

Study Completion Date

October 31, 2013

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

DRUG

NPH insulin (insulin isophane)

Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

DRUG

INSULIN GLULISINE

Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

DRUG

Regular insulin

Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia

Trial Locations (10)

72155000

Investigational Site Number 076-006, Taguatinga

80060-900

Investigational Site Number 076-007, Curitiba

60015-052

Investigational Site Number 076-010, Fortaleza

60115-282

Investigational Site Number 076-001, Fortaleza

91350-250

Investigational Site Number 076-003, Porto Alegre

01244-030

Investigational Site Number 076-005, São Paulo

01308-050

Investigational Site Number 076-013, São Paulo

01323-001

Investigational Site Number 076-004, São Paulo

04024-002

Investigational Site Number 076-002, São Paulo

o4039-000

Investigational Site Number 076-009, São Paulo